Krystal Biotech Statistics

Total Valuation

Krystal Biotech has a market cap or net worth of EUR 3.69 billion. The enterprise value is 3.00 billion.

Market Cap	3.69B
Enterprise Value	3.00B

Important Dates

The last earnings date was Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	28.94M
Shares Outstanding	n/a
Shares Change (YoY)	+1.66%
Shares Change (QoQ)	-0.41%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	22.91M

Valuation Ratios

The trailing PE ratio is 29.53 and the forward PE ratio is 20.99.

PE Ratio	29.53
Forward PE	20.99
PS Ratio	12.06
PB Ratio	4.16
P/TBV Ratio	4.16
P/FCF Ratio	23.37
P/OCF Ratio	22.18
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 22.72, with an EV/FCF ratio of 18.98.

EV / Earnings	23.99
EV / Sales	9.78
EV / EBITDA	22.72
EV / EBIT	23.13
EV / FCF	18.98

Financial Position

The company has a current ratio of 9.68, with a Debt / Equity ratio of 0.01.

Current Ratio	9.68
Quick Ratio	9.13
Debt / Equity	0.01
Debt / EBITDA	0.06
Debt / FCF	0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 15.61% and return on invested capital (ROIC) is 10.00%.

Return on Equity (ROE)	15.61%
Return on Assets (ROA)	9.23%
Return on Invested Capital (ROIC)	10.00%
Return on Capital Employed (ROCE)	14.44%
Revenue Per Employee	1.11M
Profits Per Employee	454,314
Employee Count	275
Asset Turnover	0.35
Inventory Turnover	1.10

Taxes

In the past 12 months, Krystal Biotech has paid 18.75 million in taxes.

Income Tax	18.75M
Effective Tax Rate	13.05%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	55.05
Average Volume (20 Days)	12

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.85

Income Statement

In the last 12 months, Krystal Biotech had revenue of EUR 305.86 million and earned 124.94 million in profits. Earnings per share was 4.18.

Revenue	305.86M
Gross Profit	285.58M
Operating Income	129.25M
Pretax Income	143.69M
Net Income	124.94M
EBITDA	130.41M
EBIT	129.25M
Earnings Per Share (EPS)	4.18

Full Income Statement

Balance Sheet

The company has 580.71 million in cash and 8.24 million in debt, giving a net cash position of 690.66 million.

Cash & Cash Equivalents	580.71M
Total Debt	8.24M
Net Cash	690.66M
Net Cash Per Share	n/a
Equity (Book Value)	886.11M
Book Value Per Share	30.63
Working Capital	642.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 166.38 million and capital expenditures -8.48 million, giving a free cash flow of 157.90 million.

Operating Cash Flow	166.38M
Capital Expenditures	-8.48M
Free Cash Flow	157.90M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 93.37%, with operating and profit margins of 42.26% and 40.85%.

Gross Margin	93.37%
Operating Margin	42.26%
Pretax Margin	46.98%
Profit Margin	40.85%
EBITDA Margin	42.64%
EBIT Margin	42.26%
FCF Margin	51.63%

Dividends & Yields

Krystal Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.66%
Shareholder Yield	n/a
Earnings Yield	3.39%
FCF Yield	4.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Krystal Biotech has an Altman Z-Score of 31.71 and a Piotroski F-Score of 7.

Altman Z-Score	31.71
Piotroski F-Score	7